Market Segmentation:
- By Disease Type
- Atopic Dermatitis
- Contact Dermatitis
- Seborrheic Dermatitis
- Neurodermatitis
- Nummular Dermatitis
- By Treatment Type
- Topical Treatments
- Systemic Treatments
- Phototherapy
- Biologics
- Others (Complementary and Alternative Therapies)
- Immunosuppressants
- Others (Antihistamines, Emollients)
- By Route of Administration
- Oral
- Parenteral
- Topical
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Direct Tenders, Mail Order)
- By Drug Class
- Corticosteroids
- Calcineurin Inhibitors
- Immunomodulators
- Interleukin Inhibitors
- JAK Inhibitors
- By End User
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others (Research Institutes, etc.)
- By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Atopic Dermatitis industry is USD 10.2 billion in 2023.
Rising prevalence, increasing awareness, robust pipeline, urbanization, pollution, changing lifestyles, economic development, and improving healthcare infrastructure.
High treatment costs, stringent regulatory approvals, side effects of existing treatments, and limited access in developing regions.
The leading component segment is the topical treatments segment, widely used as first-line therapy.
Sanofi, Regeneron Pharmaceuticals, Pfizer, AbbVie, Eli Lilly and Company, Novartis, LEO Pharma, Bausch Health Companies, Galderma, Mayne Pharma.
The Atopic Dermatitis Market is expected to grow at a CAGR of 13.8% from 2024 to 2031, reaching a market size of US$ 28.7 billion by 2031.
Rising prevalence, increasing awareness, robust pipeline, urbanization, pollution, changing lifestyles, economic development, and improving healthcare infrastructure.